In collaboration with the universities of Kiel, Munich, and Braunschweig, a novel bispecific antibody CD20xNKG2D was developed to enhance lymphocyte recruitment and mediate killing of B cell lymphoma cells.
In collaboration with the universities of Kiel, Munich, and Braunschweig, a novel bispecific antibody CD20xNKG2D was developed to enhance lymphocyte recruitment and mediate killing of B cell lymphoma cells.
